Literature DB >> 11082295

Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells.

R Djaborkhel1, D Tvrdík, T Eckschlager, I Raska, J Müller.   

Abstract

Transforming growth factor beta1 (TGFbeta1) induces growth arrest in many cell types, including B lymphocytes. We examined the effect of TGF on cell cycle progression of a non-Hodgkin lymphoma cell line of follicular lymphoma subtype (FL). After 48 h of TGFbeta1 (10 ng/ml) treatment, a significantly increased number of DoHH2 cells was retained in G(0)/G(1) phase. We examined the level of cell cycle components, cyclins, cyclin-dependent kinases (cdk), and their inhibitors. We found that the expression of cyclin A and p21(WAF1) molecules was primarily modulated by TGFbeta1 treatment while the expression of other regulatory components, like cyclins D, cyclin E, cdk2, cdk4, and cdk6 or p15(INK4B), p16(INK4A), and p27(KIP1) was not significantly affected. We further examined expression and activity of CREB/ATF family members to examine their roles in cyclin A inhibition. The binding activity of CREB-1 and ATF-2 to the CRE region of the cyclin A promoter was almost completely abolished due to the treatment. The total level of CREB-1, ATF-2, and ATF-3 was notably reduced. Moreover, CREB-1 was dephosphorylated due to the treatment as revealed by immunoblotting. We assume that down-regulation of cyclin A was mediated by the absence of CREB/ATF activation dimers. The profound effect on the ATF family of transcription factors indicates the complexity of TGFbeta1 action on FL B malignant cells. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082295     DOI: 10.1006/excr.2000.5047

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells.

Authors:  Ran Elkon; Chaim Linhart; Roded Sharan; Ron Shamir; Yosef Shiloh
Journal:  Genome Res       Date:  2003-05       Impact factor: 9.043

2.  Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.

Authors:  Shudan Mao; Wenqi Yang; Limei Ai; Zhe Li; Jieping Jin
Journal:  Tumour Biol       Date:  2015-07-14

3.  A novel role for polymeric immunoglobulin receptor in tumour development: beyond mucosal immunity and into hepatic cancer cell transformation.

Authors:  Brittany Dewdney; Lionel Hebbard
Journal:  Hepatobiliary Surg Nutr       Date:  2018-02       Impact factor: 7.293

4.  Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Authors:  Liu Yang; Mei Liu; Chuanzong Deng; Zhikai Gu; Yilu Gao
Journal:  Tumour Biol       Date:  2012-04-29

5.  Phosphorylation of the cyclic AMP response element binding protein mediates transforming growth factor beta-induced downregulation of cyclin A in vascular smooth muscle cells.

Authors:  Kentaro Kamiya; Kenji Sakakibara; Evan J Ryer; Raymond P Hom; Edward B Leof; K Craig Kent; Bo Liu
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

6.  Dibutyryl cAMP stimulates the proliferation of SH-SY5Y human neuroblastoma cells by up-regulating Skp2 protein.

Authors:  Chin-Ho Cho; Miran Seo; Yun-Il Lee; So-Young Kim; Hong-Duk Youn; Yong-Sung Juhnn
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-27       Impact factor: 4.553

7.  Altered expression of Smad proteins in T or NK-cell lymphomas.

Authors:  Jai Hyang Go
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

Review 8.  Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity.

Authors:  Kristian M Hargadon
Journal:  J Clin Med       Date:  2016-08-31       Impact factor: 4.241

9.  Transcriptome altered by latent human cytomegalovirus infection on THP-1 cells using RNA-seq.

Authors:  Qi Zhang; Mei-Mei Lai; Yun-Yan Lou; Bin-Han Guo; Hui-Yan Wang; Xiao-Qun Zheng
Journal:  Gene       Date:  2016-09-10       Impact factor: 3.688

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.